<code id='8C3412D133'></code><style id='8C3412D133'></style>
      • <acronym id='8C3412D133'></acronym>
      <center id='8C3412D133'><center id='8C3412D133'><tfoot id='8C3412D133'></tfoot></center><abbr id='8C3412D133'><dir id='8C3412D133'><tfoot id='8C3412D133'></tfoot><noframes id='8C3412D133'>
      • <optgroup id='8C3412D133'><strike id='8C3412D133'><sup id='8C3412D133'></sup></strike><code id='8C3412D133'></code></optgroup>
        5. <b id='8C3412D133'><label id='8C3412D133'><select id='8C3412D133'><dt id='8C3412D133'><span id='8C3412D133'></span></dt></select></label></b><u id='8C3412D133'></u>
          <i id='8C3412D133'><strike id='8C3412D133'><tt id='8C3412D133'><pre id='8C3412D133'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-28 02:33:55 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：3
                                  
                                    
          
                                   
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb
          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.
          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.
          advertisement
          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          TikTok, Instagram influencers need more rules for drug ads
                                
                            
          Next article：  
                                      
                                          Cancer drug shortages should be causing more outrage
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles